Civilization Ventures

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the barriers posed by tumors. By enhancing the effectiveness and durability of immunotherapies, OverT Bio aims to advance the healthcare field's ability to identify and ultimately cure cancer.

Siren Biotechnology is a biotech company focused on innovating cancer treatment through a unique gene therapy platform. By integrating adeno-associated virus (AAV) gene therapy with cytokine immunotherapy, Siren Biotechnology has developed a novel therapeutic approach. This combination aims to address significant challenges in cancer treatment, including delivery methods, efficacy, and toxicity, ultimately enhancing the elimination of tumor cells and stimulating anti-tumor immunity. Through this redesigned modality, the company seeks to transform the landscape of cancer therapies, offering new hope for patients facing this disease.

Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Kernal Biologics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on designing and developing mRNA immunotherapies for diseases such as COVID-19 and cancer. Founded in 2016, the company utilizes its mRNA platform to enable specific cells to produce their own therapeutic agents. Kernal's innovative approach has garnered recognition, including awards from notable organizations like Amgen and NASA. The team behind Kernal Biologics has strong ties to prestigious institutions such as MIT and Harvard, along with extensive experience in the biotech sector, which underpins their expertise in the mRNA field.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Rocket Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative gene therapies for rare and severe pediatric diseases. The company specializes in lentiviral vector and adeno-associated virus platforms to target genetic disorders. Its lead program focuses on treating Fanconi Anemia, a serious condition that leads to bone marrow failure. In addition to this, Rocket is actively researching therapies for several other bone marrow-derived disorders, including Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis. Furthermore, the company is developing an AAV-based gene therapy for Danon Disease, a multi-organ disorder associated with increased risk of cardiovascular complications. To advance its research, Rocket Pharmaceuticals maintains numerous collaborations and license agreements with prestigious institutions, enhancing its capabilities in gene therapy development. The company is headquartered in New York, New York.